STOCK TITAN

Twist Bioscience - TWST STOCK NEWS

Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.

Overview of Twist Bioscience Corp

Twist Bioscience Corp is a pioneering synthetic biology company that has redefined the process of DNA synthesis using a proprietary semiconductor-based manufacturing platform. The company leverages innovative technology to produce high-quality synthetic DNA rapidly and cost-effectively. This breakthrough approach, characterized by synthesizing DNA on silicon rather than traditional plastic wells, positions Twist Bioscience as a disruptive force in the biotechnological landscape, driving advances in applications from biomedical research to industrial biotechnology.

Proprietary Technology and Manufacturing Process

At the heart of Twist Bioscience's operations is a state-of-the-art synthetic DNA manufacturing process. By employing a 10,000-well silicon platform, the company sidesteps the limitations inherent in conventional methods. The integration of semiconductor technology not only minimizes production inefficiencies but also ensures high throughput, which is crucial for applications requiring rapid gene synthesis and customization. This technical ingenuity underpins the company's ability to deliver:

  • High-quality oligonucleotides
  • Custom genes and genetic pathways
  • Complex chassis and complete genomes

Business Model and Revenue Generation

Twist Bioscience's business model is built on the dual pillars of technology licensing and direct sales. The company generates revenue by offering its synthetic DNA products to a wide range of customers including academic research institutions, biotechnology firms, and industrial manufacturers. Its cost-effective, rapid production capabilities allow clients to accelerate their research and development efforts, thereby reducing time-to-market for various applications. This operational efficiency is not only beneficial to its clients but also reinforces the company’s reputation for reliability and scalability in the synthetic biology market.

Market Position and Competitive Landscape

Operating in a highly specialized niche, Twist Bioscience has carved a unique position in the competitive synthetic biology ecosystem. The company differentiates itself through its disruptive manufacturing process and its capacity to produce synthetic biology tools at scale. In a market where reliability, speed, and cost-efficiency are paramount, Twist Bioscience’s strategic focus on overcoming production inefficiencies positions it as a significant player. Its technology challenges traditional paradigms and compels competitors to reconsider conventional manufacturing methods, thereby affirming its role as an innovator rather than a mere participant in the industry.

Applications and Industry Impact

The technology developed by Twist Bioscience has far-reaching implications across numerous sectors. In the field of biomedical research and personalized medicine, its rapid DNA synthesis paves the way for new diagnostics, targeted therapies, and advanced research into genetic disorders. Beyond healthcare, the company’s synthetic biology tools enable innovations in sustainable chemical production and improved agricultural practices, broadening the scope of applications into:

  • Biopharmaceutical research: Accelerating drug discovery and genetic screening.
  • Industrial biotechnology: Optimizing production processes for chemicals and materials.
  • Environmental monitoring: Developing in vivo diagnostics and biodetection solutions.

This multi-sector applicability underscores the versatility and transformative potential of Twist Bioscience's platform. By industrializing the engineering of biology, the company not only enhances research capabilities but also contributes significantly to sectors that rely on synthetic DNA for innovation and efficiency.

Operational Excellence and Research Ecosystem

Central to the success of Twist Bioscience is its commitment to operational excellence and continuous innovation. The company collaborates with a diverse ecosystem of researchers, academic institutions, and industrial partners, fostering an environment where technological breakthroughs are routinely translated into practical solutions. This collaborative approach ensures that every advancement in its manufacturing process is both rigorously validated and immediately deployable across a spectrum of research and industrial applications.

Scientific and Technical Expertise

Twist Bioscience is driven by a deep reservoir of scientific and technical expertise. The company’s team, comprised of leading experts in synthetic biology, semiconductor physics, and bioengineering, is instrumental in refining its technology and pushing the boundaries of what is possible in DNA synthesis. This expertise not only strengthens the company’s competitive position but also instills confidence in its ability to deliver reliable, high-quality synthetic biology products that meet the evolving needs of modern research and industry.

Integration into the Broader Biotechnology Landscape

The innovations from Twist Bioscience resonate well within the broader biotechnology and life sciences arenas. Its approach to DNA synthesis using semiconductor-based technology is widely recognized for its potential to revolutionize how genetic materials are produced and utilized. This integration of advanced material science with biotechnology exemplifies the cross-disciplinary innovation that is becoming increasingly important. Researchers and industrial partners alike appreciate the capacity for simultaneous high throughput and high precision, enabling a smoother transition from conceptual breakthroughs to tangible products.

Commitment to Quality and Reliability

Quality control and reliability are fundamental to Twist Bioscience’s operations. The company’s advanced manufacturing process ensures consistency and precision in synthetic DNA production. By employing robust quality assurance protocols throughout its production cycle, Twist Bioscience provides products that research institutions and industry players can depend upon for critical applications. This unwavering focus on quality not only supports current operational needs but also cements the company’s reputation as a trustworthy provider of synthetic biology tools.

Position within the Competitive Landscape

While the synthetic biology sector is competitive, Twist Bioscience’s distinctive approach allows it to maintain a unique market niche. Its semiconductor-based platform, coupled with the extensive scale and precision of production, sets it apart from more traditionally operated competitors. The company’s strategy of addressing the inherent inefficiencies of standard DNA synthesis methods resonates with clients looking for innovative solutions. This unique value proposition has enabled Twist Bioscience to develop a strong foothold in its primary markets, particularly in regions known for high research and development activity.

Conclusion

In summary, Twist Bioscience Corp represents a significant advancement in synthetic biology. Through its disruptive semiconductor-based synthetic DNA platform, the company not only accelerates research and industrial processes but also redefines the standards of cost efficiency and production quality. Its integrated approach, encompassing innovative technology, rigorous quality control, a collaborative research ecosystem, and a clear focus on operational excellence, makes it a compelling case study in modern biotechnology innovations. The breadth of its applications and its ability to deliver high-quality synthetic DNA at scale underscore its impact on the biotechnology industry and its sustained position in the competitive landscape.

Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) announced plans to expand its manufacturing capabilities with a new "Factory of the Future" near Portland, Oregon. The 110,000-square-foot facility, expected to be operational in 2022, aims to create up to 400 jobs. CEO Emily M. Leproust emphasized that this facility will enhance production speed and support the growing synthetic biology and biopharma markets, facilitating aggressive growth. This strategic move aligns with Twist's mission to provide high-quality synthetic DNA through its innovative silicon platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.45%
Tags
none
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) has launched its Clonal-Ready Gene Fragments, enhancing its synthetic DNA offerings. This product aims to minimize the time and cost associated with screening for perfect clones, addressing a significant segment of the synthetic biology market. The Gene Fragments, produced via Twist's semiconductor-based platform, boast low error rates, which enhance efficiency for researchers needing smaller DNA amounts. This innovation positions Twist to better serve its customers and expand its market reach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.17%
Tags
none
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) has successfully closed its public offering of 3,211,362 shares at $110.00 each, generating approximately $323.7 million in net proceeds. The offering included shares sold by both the company and certain selling stockholders. Twist plans to utilize these funds to enhance operational capacity, increase R&D investments, and expand its manufacturing capabilities for its synthetic DNA offerings. Additionally, a portion of the proceeds may be allocated towards acquiring complementary businesses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.04%
Tags
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) has priced a public offering of 2,802,272 shares of common stock at $110.00 per share, aiming for approximately $300 million in gross proceeds. The offering includes 2,727,272 shares sold by Twist and 75,000 shares from selling stockholders. Expected to close on December 7, 2020, funds will enhance operational capacity, R&D, and IT infrastructure, with potential investments in complementary businesses. The offering is underwritten by J.P. Morgan, Goldman Sachs, Cowen, and Evercore.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.32%
Tags
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) announced its intention to conduct an underwritten public offering of up to $250 million in common stock. Additionally, certain selling stockholders plan to offer 75,000 shares. The offering includes a 30-day option for underwriters to purchase up to $37.5 million more. Twist aims to utilize net proceeds to enhance operational capacity, invest in automation and R&D, and support growth in various sectors, including NGS and DNA data storage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.57%
Tags
-
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) announced its participation in two upcoming virtual investor conferences. Emily Leproust, CEO, and Jim Thorburn, CFO, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on November 30 at 8:00 a.m. ET, and the Evercore ISI HealthCONx Conference on December 1 at 1:50 p.m. ET. Both presentations can be accessed on the company’s investor relations website, with replays available for 90 days post-event. Twist Bioscience specializes in synthetic DNA products and applications across multiple industries, including healthcare and agriculture.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
conferences
Rhea-AI Summary

Twist Bioscience reported strong financial results for fiscal year 2020 with total revenues increasing to $90.1 million from $54.4 million in fiscal 2019. Total orders rose to $116.7 million. Despite the growth, the company experienced a net loss of $139.9 million, or $3.57 per share. The fourth quarter also saw revenue growth to $32.4 million from $15.7 million year-over-year. With a strong cash position of $290 million, Twist plans aggressive growth in fiscal 2021, focusing on synthetic biology, NGS, and biopharma technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
-
Rhea-AI Summary

Twist Bioscience Corporation (Nasdaq: TWST) announced promising preclinical data for three proprietary antibodies targeting the S1 protein of SARS-CoV-2. The antibodies, TB202-3 and TB202-63, demonstrated protection against weight loss in a hamster model at a low dose of 1 mg/kg. TB181-36, discovered in collaboration with Vanderbilt University, also showed protective effects at doses of 5 mg/kg and 10 mg/kg. These results suggest potential for new COVID-19 treatment approaches, including a preventive nasal spray, amid rising global infection cases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
-
Rhea-AI Summary

Twist Bioscience (TWST) and Biotia have launched the SARS-CoV-2 Next-Generation Sequencing (NGS) Assay, a new research tool for COVID-19 sequencing and surveillance. This highly sensitive assay allows for extensive monitoring of the virus's genetic changes, surpassing standard PCR tests in capability. Validated on a NextSeq® sequencer, the assay provides crucial sequence data to aid researchers in tracking mutations and understanding the virus's evolution. The assay targets various sample types, offering public health insights, particularly during ongoing pandemic waves.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
none
Rhea-AI Summary

Twist Bioscience Corporation (NASDAQ: TWST) has launched the Comprehensive Viral Research Panel, a next-generation sequencing (NGS) tool that identifies over 3,000 viral genomes. This panel aims to assist in detecting new viral species and supports metagenomic surveillance. It features over one million unique probes and integrates with the One Codex analysis platform for streamlined results. The product is designed for research use only and contributes to public health efforts in monitoring viral diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
none

FAQ

What is the current stock price of Twist Bioscience (TWST)?

The current stock price of Twist Bioscience (TWST) is $36.19 as of April 4, 2025.

What is the market cap of Twist Bioscience (TWST)?

The market cap of Twist Bioscience (TWST) is approximately 2.2B.

What is Twist Bioscience's core business?

Twist Bioscience focuses on synthetic biology by utilizing a proprietary semiconductor-based platform to synthesize high-quality DNA. Its core business involves manufacturing synthetic DNA for research, industrial biotechnology, and biomedical applications.

How does Twist Bioscience's technology differ from traditional methods?

The company synthesizes DNA on silicon rather than on conventional plastic plates, enabling cost-effective, rapid, and high-throughput production while overcoming common inefficiencies in traditional synthesis methods.

Which industries benefit from Twist Bioscience's products?

Industries ranging from biomedical research and personalized medicine to industrial biotechnology and sustainable chemical production benefit from their high-quality synthetic DNA products.

What are the primary products provided by Twist Bioscience?

Twist Bioscience produces a range of synthetic biology tools including oligonucleotides, genes, genetic pathways, chassis, and complete genomes, all synthesized using their advanced silicon-based platform.

How does the company's business model support its operations?

The company generates revenue through direct sales and technology licensing, offering high-quality synthetic DNA products that enhance research capabilities and industrial production efficiency.

What competitive advantages does Twist Bioscience hold in the synthetic biology market?

Their proprietary technology, which leverages semiconductor manufacturing techniques, allows them to produce DNA faster and more cost-effectively than traditional methods, positioning them uniquely in the competitive landscape.

Who are the primary customers of Twist Bioscience?

Twist Bioscience serves a diverse customer base including academic research institutions, biotechnology companies, and industrial manufacturers requiring reliable synthetic DNA production for various applications.

How does Twist Bioscience ensure the quality of its synthetic DNA products?

By integrating rigorous quality control protocols within its manufacturing process, the company ensures consistent and precise production, making its products dependable for critical research and industrial applications.
Twist Bioscience

Nasdaq:TWST

TWST Rankings

TWST Stock Data

2.24B
58.41M
2.16%
112.29%
15.59%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO